July 30, 2024 02:04 PM EDT
Pharma
FDA+

FDA shoots down sec­ond No­var­tis pe­ti­tion seek­ing to halt En­tresto gener­ics

Zachary Brennan

Senior Editor

Fol­low­ing the FDA’s de­ci­sion to ap­prove the first En­tresto gener­ics in May, the agency has told No­var­tis that its lat­est ef­fort …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times